Abstract
Processing of information by the central nervous system (CNS) depends on the dendritic morphology of postsynaptic neurons. The patterning of dendrites is determined by extrinsic and intrinsic factors that promote the activation of cellular signaling pathways. These factors and signaling cascades may lead to the transcriptional activation of regulators of neuronal morphology. Interestingly, when there is an abnormal decrease in the number of dendrite branches and disruption of proper networks, neurodegenerative diseases, including Rett Syndrome, autism, and mental retardation, may result. In this review, we evaluate the potential of regulators of dendrite patterning as targets for drug design for the treatment of neurodegenerative diseases and altered neuronal growth in the CNS. Particular attention is directed towards a specific regulator of dendrite branching reported by our group, cypin (cytosolic PSD-95 interactor). We discuss this novel intrinsic regulator of dendrite branching as an innovative pharmacological target for the use of computer-aided rational drug design to control guanine levels, microtubule assembly, and neuronal differentiation during CNS development and in disease states.
Keywords: Dendrite branching, dendrite development, signaling pathways, transcriptional regulation, neurotrophins, cypin, guanine deaminase, neurological disorders
Central Nervous System Agents in Medicinal Chemistry
Title: Novel Pharmacological Targets for Controlling Dendrite Branching and Growth During Neuronal Development
Volume: 8 Issue: 2
Author(s): Jose R. Fernandez and Bonnie L. Firestein
Affiliation:
Keywords: Dendrite branching, dendrite development, signaling pathways, transcriptional regulation, neurotrophins, cypin, guanine deaminase, neurological disorders
Abstract: Processing of information by the central nervous system (CNS) depends on the dendritic morphology of postsynaptic neurons. The patterning of dendrites is determined by extrinsic and intrinsic factors that promote the activation of cellular signaling pathways. These factors and signaling cascades may lead to the transcriptional activation of regulators of neuronal morphology. Interestingly, when there is an abnormal decrease in the number of dendrite branches and disruption of proper networks, neurodegenerative diseases, including Rett Syndrome, autism, and mental retardation, may result. In this review, we evaluate the potential of regulators of dendrite patterning as targets for drug design for the treatment of neurodegenerative diseases and altered neuronal growth in the CNS. Particular attention is directed towards a specific regulator of dendrite branching reported by our group, cypin (cytosolic PSD-95 interactor). We discuss this novel intrinsic regulator of dendrite branching as an innovative pharmacological target for the use of computer-aided rational drug design to control guanine levels, microtubule assembly, and neuronal differentiation during CNS development and in disease states.
Export Options
About this article
Cite this article as:
Fernandez R. Jose and Firestein L. Bonnie, Novel Pharmacological Targets for Controlling Dendrite Branching and Growth During Neuronal Development, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (2) . https://dx.doi.org/10.2174/187152408784533923
DOI https://dx.doi.org/10.2174/187152408784533923 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress and Neurodegenerative Diseases: Looking for a Therapeutic Solution Inspired on Benzopyran Chemistry
Current Topics in Medicinal Chemistry Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Synthesis, Biological Activity of Thiazolidinones Bearing Indoline Moiety and Isatin Based Hybrids
Mini-Reviews in Organic Chemistry Infectious Agents and Neurodegenerative Diseases: Exploring the Links
Current Topics in Medicinal Chemistry Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers
Current Alzheimer Research Long Non-coding RNA MALAT1 Inhibits Neuron Apoptosis and Neuroinflammation While Stimulates Neurite Outgrowth and Its Correlation With MiR-125b Mediates PTGS2, CDK5 and FOXQ1 in Alzheimer's Disease
Current Alzheimer Research Medicinal Plants: A Natural Chaperones Source for Treating Neurological Disorders
Protein & Peptide Letters Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Current Pharmaceutical Design Antioxidants and its Properties as Affected by Extrusion Process: A Review
Recent Patents on Food, Nutrition & Agriculture Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) Autoimmunity and Frontotemporal Dementia
Current Alzheimer Research Diagnoses of Pathological States Based on Acetylcholinesterase and Butyrylcholinesterase
Current Medicinal Chemistry Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Current Pharmaceutical Design Insulin Resistance in Alzheimer Disease: p53 and MicroRNAs as Important Players
Current Topics in Medicinal Chemistry Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Current Drug Targets Novel Indole-Isoxazole Hybrids: Synthesis and In Vitro Anti-Cholinesterase Activity
Letters in Drug Design & Discovery Old Friends in New Constellations - the Hematopoetic Growth Factors G-CSF, GMCSF, and EPO for the Treatment of Neurological Diseases
Current Medicinal Chemistry New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function
Current Neuropharmacology The Small Heat Shock Protein HspB8: Role in Nervous System Physiology and Pathology
CNS & Neurological Disorders - Drug Targets